RVL

Upneeq® Wins 2024 Shape Skin Award, “Best for Lift”, in the Professional Treatment Category

Retrieved on: 
星期五, 五月 17, 2024
Cosmetics, Men, Alternative Medicine, Retail, Health, Consumer, Pharmaceutical, Optical, Bridal, General Health, LGBTQ+, Fitness & Nutrition, Women, Seniors, Blood pressure, Patient, Telecanthus, Headache, Xanthine oxidase inhibitor, Pressure, Myasthenia gravis, Mouth, Eye injury, Blepharoplasty, Risk, Heart, FDA, Shape (magazine), Digital, Glaucoma, Stroke, Safety, Prostate, RVL, Dermatology, MD, Hypertension, Human, Eye, Aneurysm, Brain, Horner's syndrome, Beauty, Skin, Multimedia, Pharmaceutical industry

RVL Pharmaceuticals announced today that its prescription eye drop, Upneeq® (oxymetazoline hydrochloride ophthalmic solution), 0.1% has been selected as a 2024 Shape Skin Award winner by Shape Magazine, named “Best for Lift” in the professional category.

Key Points: 
  • RVL Pharmaceuticals announced today that its prescription eye drop, Upneeq® (oxymetazoline hydrochloride ophthalmic solution), 0.1% has been selected as a 2024 Shape Skin Award winner by Shape Magazine, named “Best for Lift” in the professional category.
  • The product was also named as a "Best Professional Grade'' treatment by editors in 2022 and received a 2023 Shape Beauty Award for “Best In-Office" treatments.
  • 37 winners were ultimately chosen, and judges awarded Upneeq for its subtle but noticeable lift for droopy eyelids.
  • “Shape is an empowering and trusted voice in health and beauty with a committed community to quality self-care.

RVL Completes Financial Restructuring

Retrieved on: 
星期一, 十一月 27, 2023
Plan, RVL, Bankruptcy, Pharmacy, Patient, United States bankruptcy court, Blepharoplasty

BRIDGEWATER, N.J., Nov. 27, 2023 (GLOBE NEWSWIRE) --  RVL Pharmaceuticals, Inc. (“RVL” or the “Company”), a specialty pharmaceutical company focused on the commercialization of UPNEEQ® (oxymetazoline hydrochloride ophthalmic solution), 0.1%, for the treatment of acquired blepharoptosis, or droopy eyelids, in adults, today announced that it and its wholly-owned U.S. operating subsidiary RVL Pharmacy, LLC (collectively, the “RVL Subsidiaries”), successfully emerged from their Chapter 11 cases on November 22, 2023 following the confirmation by the United States Bankruptcy Court for the District of Delaware of their Plan of Reorganization (“Plan”) on November 20, 2023. RevitaLid Pharmaceutical Corp., previously the direct parent company of RVL Pharmaceuticals, Inc, concurrently emerged from its Chapter 11 case, though will be wound down under the Plan.

Key Points: 
  • RevitaLid Pharmaceutical Corp., previously the direct parent company of RVL Pharmaceuticals, Inc, concurrently emerged from its Chapter 11 case, though will be wound down under the Plan.
  • “Upon emergence, the RVL Subsidiaries are well-positioned to invest in UPNEEQ, drive their strategic initiatives, and continue to deliver high-quality, innovative ocular and aesthetic solutions for patients and healthcare partners,” said Brian Markison, Chief Executive Officer of the Company.
  • The Plan was unanimously supported by the RVL Subsidiaries’ sole secured lender (funds managed by Athyrium Capital Management, LP (“Athyrium”)) and other key stakeholders.
  • It is expected the wind-down of the Company’s former public parent company, RVL Pharmaceuticals plc, and its subsidiaries other than the RVL Subsidiaries will promptly commence, and RVL Pharmaceuticals plc’s public equity is expected to be cancelled upon completion of its wind-down during 2024, resulting in no recovery to public shareholders.

RVL Pharmaceuticals plc Announces Prepackaged Reorganization of Certain U.S. Subsidiaries

Retrieved on: 
星期四, 十月 12, 2023
Bankruptcy, Pharmacy, Interest, LLP, RVL, Ernst & Young, Corporate action, Growth, United States bankruptcy court, United States Bankruptcy Court for the Southern District of New York, Ropes & Gray, Blepharoplasty, Patient, Security (finance), Financial services, Athyrium

BRIDGEWATER, N.J., Oct. 12, 2023 (GLOBE NEWSWIRE) -- RVL Pharmaceuticals plc (“RVL” or “the Company”), a specialty pharmaceutical company focused on the commercialization of UPNEEQ® (oxymetazoline hydrochloride ophthalmic solution), 0.1%, for the treatment of acquired blepharoptosis, or droopy eyelid, in adults, today announced that certain of its U.S. operating subsidiaries, RevitaLid Pharmaceutical Corp., RVL Pharmaceuticals, Inc. and RVL Pharmacy, LLC (the “RVL Subsidiaries”), have reached an agreement with their sole secured lenders, funds managed by Athyrium Capital Management (“Athyrium”), and other key stakeholders, to effectuate a change of control transaction through prepackaged bankruptcy cases commenced in the United States Bankruptcy Court for the District of Delaware today (the “Reorganization”). The Reorganization provides a structured pathway for the RVL Subsidiaries to significantly reduce their debt, while enabling them to streamline operations, maintain jobs and position themselves under new ownership. As a result of the Reorganization, RVL is expected to commence the wind-down of any remaining operations of the Company and its subsidiaries, other than the RVL Subsidiaries. RVL’s public equity is expected to be cancelled upon completion of its wind-down, anticipated to be during 2024, likely resulting in no recovery to public shareholders.

Key Points: 
  • The Reorganization provides a structured pathway for the RVL Subsidiaries to significantly reduce their debt, while enabling them to streamline operations, maintain jobs and position themselves under new ownership.
  • As a result of the Reorganization, RVL is expected to commence the wind-down of any remaining operations of the Company and its subsidiaries, other than the RVL Subsidiaries.
  • The Reorganization contemplates that all of RVL Subsidiaries’ vendors, suppliers, and customers will be unaffected by the Reorganization, and their employees will remain employed by these entities.
  • The RVL Subsidiaries have filed a series of “First Day Motions” with the United States Bankruptcy Court for the District of Delaware.

RVL Pharmaceuticals plc Reports Second Quarter 2023 Financial Results; Provides Update on Strategic Business Review

Retrieved on: 
星期一, 八月 14, 2023
Insurance, Blepharoplasty, Marketing, Tax, GAAP, Sale, Medication, Development, Depreciation, Growth, TAM, Research, Adjustment, Colin Markison, RVL, Bank, Pharmaceutical industry, Fine chemical, Reinsurance, Cryptocurrency, Bookkeeping, EBITDA, Athyrium

-- The Company streamlined operating expense in order to extend runway, optimize marketing mix, and support strategic business development --

Key Points: 
  • UPNEEQ net product sales were $8.3 million, a decrease of $0.1 million, or 2%, from the second quarter of 2022.
  • 5,400 cumulative unique medical aesthetics practices had placed orders for UPNEEQ at quarter end, an increase of 13% from the end of the first quarter of 2023.
  • Adjusted EBITDA1 loss was $(7.4) million, compared to an Adjusted EBITDA loss of $(11.8) million in the second quarter of 2022.
  • Adjusted EBITDA loss is reconciled from net loss, the most comparable GAAP financial measure, in the attached table “RVL Pharmaceuticals plc - GAAP to Non-GAAP Reconciliations” at the end of this press release.

RVL Pharmaceuticals plc Reports First Quarter 2023 Financial Results; Provides Commercial Update

Retrieved on: 
星期四, 五月 11, 2023
Insurance, Telehealth, Blepharoplasty, Marketing, Tax, Optometry, Prescription, GAAP, Research, Absorption, Pharmacy, Sale, Medication, Depreciation, Growth, Adjustment, Colin Markison, RVL, Pharmaceutical industry, Video game, Cryptocurrency, Bank, Bookkeeping, EBITDA

-- UPNEEQ Won “Best Eye Drop for Drooping Lids” NewBeauty in 13th Annual Beauty Awards, selected from among 10,000 entrants --

Key Points: 
  • In fact, monthly pharmacy prescriptions reached an all-time high during the first quarter of 2023, despite the absence of personal promotional support.
  • Additionally, momentum in aesthetics continued, with growth in the percentage of reorders and in new account openings during the quarter.
  • UPNEEQ net product sales were $8.8 million, an increase of $2.9 million, or 49%, over the first quarter of 2022.
  • Adjusted EBITDA loss is reconciled from net loss, the most comparable GAAP financial measure, in the attached table “RVL Pharmaceuticals plc - GAAP to Non-GAAP Reconciliations” at the end of this press release.

RVL Pharmaceuticals plc Reports Fourth Quarter and Full Year 2022 Financial Results; Provides Commercial Update

Retrieved on: 
星期一, 三月 20, 2023
Telehealth, Blepharoplasty, Marketing, Tax, GAAP, Research, Absorption, Sale, Medication, Traction, Depreciation, Growth, Adjustment, FDA, Colin Markison, RVL, Video game, Pharmaceutical industry, Bank, Cryptocurrency, Bookkeeping, EBITDA

BRIDGEWATER, N.J., March 20, 2023 (GLOBE NEWSWIRE) -- RVL Pharmaceuticals plc (Nasdaq: RVLP) (“RVL” or the “Company”), a specialty pharmaceutical company, today announced financial results and business highlights for the three months and full year ended December 31, 2022.

Key Points: 
  • Launched into the medical aesthetics market in February 2022 and ended the year with approximately 4,300 new customer practices having ordered UPNEEQ.
  • Selectively opened a telemedicine channel beginning in the third quarter of 2022.
  • On January 9, 2023, the Company announced preliminary fourth quarter and full year 2022 UPNEEQ net product sales of approximately $12.1 million and $36.5 million, respectively.
  • UPNEEQ net product sales were $9.8 million, an increase of $6.7 million, or 216%, over the fourth quarter of 2021.

RVL Pharmaceuticals plc Announces Preliminary Fourth Quarter Sequential Growth of 21% and Full Year 2022 UPNEEQ® Net Product Sales

Retrieved on: 
星期一, 一月 9, 2023
Cardiovascular disease, Security (finance), Xanthine oxidase inhibitor, Hypertension, Orthostatic hypotension, Aneurysm, Eye injury, Glycosidic bond, Focal neurologic signs, Headache, Blood pressure, FDA, Risk, Food and Drug Administration, Ptosis, Hypotension, Glaucoma, Telehealth, Orbit, Blepharoplasty, Marketing, Patient, Food, Growth, Annual report, Metabolism, Horner's syndrome, Duane syndrome, Ophthalmoparesis, Stroke, RVL, Beta blocker, Nature, Eye, Myasthenia gravis, Pharmaceutical industry, Phosphorus

BRIDGEWATER, N.J., Jan. 09, 2023 (GLOBE NEWSWIRE) -- RVL Pharmaceuticals plc (Nasdaq: RVLP) (“RVL” or the “Company”), a specialty pharmaceutical company, today announced preliminary fourth quarter and full year 2022 net product sales of UPNEEQ® (oxymetazoline hydrochloride ophthalmic solution), 0.1%, the first and only U.S. Food and Drug Administration (“FDA”)-approved ophthalmic solution for blepharoptosis, or droopy eyelids, of approximately $12.1 million and $36.5 million, respectively. The preliminary fourth quarter 2022 net product sales of UPNEEQ represent a sequential increase of 21% from the third quarter 2022. The Company also announced that from February through year-end 2022 it had received orders from approximately 4,300 cumulative unique medical aesthetics practices.

Key Points: 
  • The preliminary fourth quarter 2022 net product sales of UPNEEQ represent a sequential increase of 21% from the third quarter 2022.
  • “We are proud of our progress in the fourth quarter, notably the continued upward trajectory of net product sales for UPNEEQ.
  • On a full-year basis, we expect our UPNEEQ revenues to exceed $36 million, representing nearly 400% growth over 2021.
  • The financial and operating data for the fourth quarter of 2022 and for the full year 2022 is preliminary and may change.

RVL Pharmaceuticals plc Announces Preliminary Third Quarter 2022 UPNEEQ® Net Product Sales

Retrieved on: 
星期二, 十月 18, 2022
U.S. Securities and Exchange Commission, Hypertension, Cardiovascular disease, Risk, Mission statement, RVL, Growth, Orthostatic hypotension, Stroke, Focal neurologic signs, Glycosidic bond, Horner's syndrome, Ptosis, Annual report, Patient, Beta blocker, Duane syndrome, Security (finance), Blood pressure, Nasdaq, Myasthenia gravis, Eye, Glaucoma, Xanthine oxidase inhibitor, Food, Company, Blepharoplasty, Food and Drug Administration, Marketing, Ophthalmoparesis, Headache, Eye injury, Nature, GLOBE, Metabolism, Hypotension, Terminology, FDA, Aneurysm, Orbit, Video game, Pharmaceutical industry, Phosphorus

BRIDGEWATER, N.J., Oct. 18, 2022 (GLOBE NEWSWIRE) -- RVL Pharmaceuticals plc (Nasdaq: RVLP) (“RVL” or the “Company”), a specialty pharmaceutical company, today announced preliminary third quarter 2022 net product sales of UPNEEQ® (oxymetazoline hydrochloride ophthalmic solution), 0.1%, the first and only U.S. Food and Drug Administration (“FDA”)-approved ophthalmic solution for blepharoptosis, or droopy eyelids, of approximately $10.0 million. The Company also announced that from February through September of 2022 it had received orders from approximately 3,500 cumulative unique medical aesthetics practices. RVL further revised its guidance for net product sales of UPNEEQ for the fourth quarter of 2022, indicating an expectation of $12 to $14 million, representing sequential growth of 20% to 40% compared to the third quarter of 2022.

Key Points: 
  • --Expects third quarter 2022 preliminary UPNEEQ net product sales of approximately $10.0 million, representing an increase of 19% over the second quarter 2022--
    --Third quarter 2022 net product sales growth contributed to approximately $24.4 million in sales for the nine months ended September 30, 2022--
    --Approximately 3,500 cumulative unique medical aesthetics practices placed orders for UPNEEQ through the end of the third quarter 2022, a 59% increase from the end of the second quarter 2022--
    --Anticipates fourth quarter 2022 UPNEEQ net product sales to grow approximately 20% - 40% over the third quarter 2022, representing sales of approximately $12 - $14 million--
    BRIDGEWATER, N.J., Oct. 18, 2022 (GLOBE NEWSWIRE) -- RVL Pharmaceuticals plc (Nasdaq: RVLP) (RVL or the Company), a specialty pharmaceutical company, today announced preliminary third quarter 2022 net product sales of UPNEEQ (oxymetazoline hydrochloride ophthalmic solution), 0.1%, the first and only U.S. Food and Drug Administration (FDA)-approved ophthalmic solution for blepharoptosis, or droopy eyelids, of approximately $10.0 million.
  • RVL further revised its guidance for net product sales of UPNEEQ for the fourth quarter of 2022, indicating an expectation of $12 to $14 million, representing sequential growth of 20% to 40% compared to the third quarter of 2022.
  • The financial and operating data for the third quarter of 2022 is preliminary and may change.
  • In addition, the Companys estimate of UPNEEQ net product sales for the third quarter of 2022 should not be viewed as a substitute for full financial statements for the third quarter of 2022 prepared in accordance with U.S. generally accepted accounting standards.

Revision Skincare® Announces Strategic Partnership with RVL Pharmaceuticals plc

Retrieved on: 
星期二, 八月 30, 2022
Cardiovascular disease, Ptosis, Partnership, Blepharoplasty, Focal neurologic signs, CEO, Eye injury, Research, Ophthalmoparesis, Horner's syndrome, Duane syndrome, Solution, Peptide, Glaucoma, Mark (given name), Revision, Orthostatic hypotension, Skin, Orbit, Headache, Xanthine oxidase inhibitor, GLOBE, Patient, Nasdaq, FDA, Stroke, Blood pressure, Hypertension, Hypotension, Risk, Aneurysm, Glycosidic bond, RVL, Eye, Industry, Metabolism, Myasthenia gravis, Marketing, Pharmaceutical industry, Phosphorus

DALLAS and BRIDGEWATER, N.J., Aug. 30, 2022 (GLOBE NEWSWIRE) -- Revision Skincare, a leading medical-grade professional skincare brand, announced today a partnership with RVL Pharmaceuticals plc (Nasdaq: RVLP) (RVL), the owner of UPNEEQ, the first and only FDA-approved prescription eye drop for the treatment of acquired ptosis (low-lying lids) in adults.

Key Points: 
  • DALLAS and BRIDGEWATER, N.J., Aug. 30, 2022 (GLOBE NEWSWIRE) -- Revision Skincare, a leading medical-grade professional skincare brand, announced today a partnership with RVL Pharmaceuticals plc (Nasdaq: RVLP) (RVL), the owner of UPNEEQ, the first and only FDA-approved prescription eye drop for the treatment of acquired ptosis (low-lying lids) in adults.
  • This strategic partnership pairs two unique disruptors within the aesthetics and skincare industries, both focused on providing patients with high-quality results.
  • We are excited to join this mission with RVL to offer breakthrough patient solutions, said Maria Carell, CEO and President of Revision Skincare.
  • Through the partnership, Revision Skincare and RVL Pharmaceuticals will bring broader access to revolutionary innovations like DEJ Eye Cream, Revox Line Relaxer, and UPNEEQ.

Revision Skincare® Announces Strategic Partnership with RVL Pharmaceuticals, Inc.

Retrieved on: 
星期一, 八月 29, 2022
Cream, Cardiovascular disease, Ptosis, Partnership, Blepharoplasty, Focal neurologic signs, CEO, Eye injury, Research, Ophthalmoparesis, Horner's syndrome, Duane syndrome, Solution, Peptide, Glaucoma, Mark (given name), Orthostatic hypotension, Skin, Beta blocker, Orbit, Headache, Xanthine oxidase inhibitor, Patient, FDA, History, Stroke, Blood pressure, Hypertension, Hypotension, Risk, Aneurysm, Glycosidic bond, RVL, Eye, Industry, Metabolism, Myasthenia gravis, Marketing, Pharmaceutical industry, Phosphorus

This strategic partnership pairs two unique disruptors within the aesthetics and skincare industries, both focused on providing patients with high-quality results.

Key Points: 
  • This strategic partnership pairs two unique disruptors within the aesthetics and skincare industries, both focused on providing patients with high-quality results.
  • We are excited to join this mission with RVL to offer breakthrough patient solutions," said Maria Carell, CEO, and President, Revision Skincare.
  • Through the partnership, Revision Skincare and RVL Pharmaceuticals will bring broader access to revolutionary innovations like DEJ Eye Cream, Revox Line Relaxer, and UPNEEQ.
  • Revision Skincare is an industry leader in developing clinically-validated, high potency, transformative skincare products.